Mankind Pharma543904Pharmaceuticals
Stock rose 8-9% after strong Q2 FY27 results and bullish brokerage commentary from Kotak and Jefferies
By ScoutQuest · · 1 min read
- Stock rise
- 8 to 9 percent
- Kotak target price
- 3,035 rupees
- Q1 domestic organic growth
- 10 percent
- Q2 domestic organic growth
- 14 percent
- Sales CAGR FY26-29
- 20 percent
Heard on business television between 13:17:14 - 13:20:14 IST.
- Kotak maintained buy with target price of 3,035 rupees, citing organic domestic growth accelerating to 14% YoY in Q2 from 10% in Q1, and baking in 20% sales CAGR from FY26-29.
- Jefferies maintained buy but cut target price, saying Q2 was a beat driven by domestic growth and export momentum leading to gross margin gains and operating leverage.
- Domestic formulation grew 16% while muted consumer healthcare growth was flagged as the weak point by both brokerages and management.
- Jefferies said improving growth outlook drives a 33% EBITDA increase from FY27 to FY29.
- Stock rose 8-9% on the back of solid Q2 numbers and positive brokerage and management commentary.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Mankind Pharma
Mankind Pharma investor deck: FY26 revenue crosses ₹14.2k Cr, chronic share targeted at ~50% by FY30, 70% stake in Belgian CAR-T firm ACTx
27 Oct 2026
Mankind Pharma's strong Q2 results won brokerage support, with Jefferies and Kotak retaining buy ratings
27 Oct 2026
Mankind Pharma shares jumped 9% after Q2 earnings beat driven by strong domestic pharma growth and margin expansion
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
The call above is Kotak Institutional Equities's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.